Health News

GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment.

Read more

Filed under: Pharmacy News
Tags: Drug, leukemia, Pharmacy

Related posts

• Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia (0)
  Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML)... Read more [tags] Pharmacy News [/tags]
  
  
• Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients (0)
  Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology. Read more [tags] Pharmacy News [/tags]
  
  
• Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial (0)
  VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary [...]
  
  
• Vion Pharmaceuticals Announces Results Of The Oncologic Drugs Advisory Committee Meeting For Onrigin(TM) (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). [...]
  
  
• Vion Pharmaceuticals Announces Filing Of Special Protocol Assessment For Onrigin(TM) (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML)... Read [...]